Cas:10065-79-9 Dibenzyl carbonimidoylbiscarbamate manufacturer & supplier

Chemical Name:Dibenzyl carbonimidoylbiscarbamate

CAS.NO:10065-79-9

Synonyms:N,N’-Dicarbamylformamidine;FORMAMIDINE,N,N’-DICARBAMOYL;N,N’-bis-Cbz-guanidine;Urea,1′-methylidynedi;Formamidine,N’-dicarbamoyl;N,N’-di-Cbz-guanidine;Carbamic acid, N,N’-carbonimidoylbis-, bis(phenylmethyl) ester;Dibenzyl carbonimidoylbiscarbamate;N,N’-Dicarbamoylformamidine;Urea,1,1′-methylidynedi;N,N’-Dicarbonylformamidin;N1,N3-Dibenzyloxycarbonylguanidin;N,N’-bis(benzyloxycarbonyl)guanidine;N,N’-di(benzyloxycarbonyl)guanidine

Molecular Formula:C₁₇H₁₇N₃O₄

Molecular Weight:327.335

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.2±0.1 g/cm3

Index of Refraction:1.586

PSA:100.51000

Exact Mass:327.121918

LogP:2.55

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N,N’-Dicarbamylformamidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N’-di(benzyloxycarbonyl)guanidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N’-Dicarbamylformamidine Use and application,Formamidine,N’-dicarbamoyl technical grade,usp/ep/jp grade.

Related News: It is frequently associated with the presence of blasts or leukemic cells in the marrow. Dibenzyl carbonimidoylbiscarbamate manufacturer Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined. Dibenzyl carbonimidoylbiscarbamate supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). Dibenzyl carbonimidoylbiscarbamate vendor Both patients were being treated in isolation units at a Manila hospital. Dibenzyl carbonimidoylbiscarbamate factory It is frequently associated with the presence of blasts or leukemic cells in the marrow.